Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes

International Journal of Antimicrobial Agents

Volumn 43, Issue 6, 2014, Pages 497-507

  Lode, Hartmut M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antimicrobial therapy; Clinical efficacy; Fluoroquinolones; Resistance; Safety; Susceptibility

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BESIFLOXACIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFUROXIME AXETIL; CINOXACIN; CIPROFLOXACIN; CLINDAMYCIN; DELAFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; IMIPENEM; JNJ 2; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ACUTE EXACERBATION OF CHRONIC BRONCHITIS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL SINUSITIS; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG PENETRATION; DRUG TOLERABILITY; DRUG USE; GRAM NEGATIVE INFECTION; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; URINARY TRACT INFECTION; BACTERIA; BACTERIAL INFECTIONS; DRUG EFFECTS; DRUG THERAPY; STANDARDS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; FLUOROQUINOLONES; HUMANS;

EID: 84902119644     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.02.014     Document Type: Short Survey

References (172)

1. M.I. Andersson, and A.P. MacGowan Development of the quinolones J Antimicrob Chemother 51 Suppl. 1 2003 1 11 (Pubitemid 36622099)
2. F.J. Martinez Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients Clin Infect Dis 38 Suppl. 4 2004 S328 S340 (Pubitemid 38669888)
3. B.I. Davies, F.P.V. Maesen, and C. Baur Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis Eur J Clin Microbiol 5 1986 226 231 (Pubitemid 16112926)
4. G. Cornaglia, R. Pompei, B. Dainelli, and G. Satta In vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern European hospital Antimicrob Agents Chemother 31 1987 1651 1655 (Pubitemid 17140831)
5. S.N. Patel, A. McGeer, R. Melano, G.J. Tyrrell, K. Green, D.R. Pillai Canadian Bacterial Surveillance Network Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada Antimicrob Agents Chemother 55 2011 3703 3708
6. S.M. Bhavnani, J.P. Hammel, R.N. Jones, and P.G. Ambrose Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States Diagn Microbiol Infect Dis 51 2005 31 37 (Pubitemid 40040565)
7. J.A. Karlowsky, H.J. Adam, M. Desjardins, P.R. Lagacé-Wiens, D.J. Hoban, G.G. Zhanel Canadian Antimicrobial Resistance Alliance Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals J Antimicrob Chemother 68 Suppl. 1 2013 i39 i46
8. H. Wang, M. Chen, Y. Xu, H. Sun, Q. Yang, and Y. Hu et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010 Int J Antimicrob Agents 38 2011 376 383
9. C. Zhao, H. Sun, H. Wang, Y. Liu, B. Hu, and Y. Yu et al. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010) Diagn Microbiol Infect Dis 73 2012 174 181
10. E. Jacobs, A. Dalhoff, and G. Korfmann Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study) Int J Antimicrob Agents 33 2009 52 57
11. M.A. Pfaller, D.J. Farrell, H.S. Sader, and R.N. Jones AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States Clin Infect Dis 55 Suppl. 3 2012 S187 S193
12. T.K. Ling, J. Xiong, Y. Yu, C.C. Lee, H. Ye, and P.M. Hawkey Multicenter antimicrobial susceptibility survey of Gram-negative bacteria isolated from patients with community-acquired infections in the People's Republic of China Antimicrob Agents Chemother 50 2006 374 378 (Pubitemid 43042951)
13. A.C. Gales, M. Castanheira, R.N. Jones, and H.S. Sader Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010) Diagn Microbiol Infect Dis 73 2012 354 360
14. S.K. Bouchillon, D.J. Hoban, B.M. Johnson, J.L. Johnson, A. Hsiung, and M.J. Dowzicky et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004) Diagn Microbiol Infect Dis 52 2005 173 179 (Pubitemid 41133542)
15. H.S. Sader, D. Biek, I. Critchley, R.K. Flamm, and R.N. Jones Antimicrobial activity of the new cephalosporin ceftaroline tested against bacterial isolates from surgical skin and skin structure infections in USA medical centers (2008-2011) 32nd annual meeting of the Surgical Infection Society 18-21 April 2012, Dallas, TX 2012 Surgical Infection Society [poster 12]
16. H.S. Sader, R.K. Flamm, and R.N. Jones Antimicrobial activity of ceftaroline and comparator agents tested against organisms causing skin and soft tissue infections in European medical centres (2011) 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27-30 April 2013, Berlin, Germany 2013 European Society of Clinical Microbiology and Infectious Diseases Basel, Switzerland [poster 1619]
17. R.E. Mendes, R.N. Jones, R.K. Flamm, M. Castanheira, B. Hu, and Y. Ni et al. Recent resistance surveillance results from 12 medical centres across China (2011) 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR) 13-15 March 2013, Kuala Lumpur, Malaysia 2013 Malaysian Society for Infectious Diseases and Chemotherapy [poster 113]
18. R.E. Mendes, R.N. Jones, M. Mendosa, M. Castanheira, and J.M. Bell et al. Emerging Markets Resistance Surveillance Programme report for 12 Asia-Pacific nations (2011) 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR) 13-15 March 2013, Kuala Lumpur, Malaysia 2013 Malaysian Society for Infectious Diseases and Chemotherapy [poster 179]
19. H. Hayami, S. Takahashi, K. Ishikawa, M. Yasuda, S. Yamamoto, and S. Uehara et al. Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese Surveillance Committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus J Infect Chemother 19 2013 393 403
20. R.N. Jones, H.S. Sader, R.K. Flamm, J.M. Streit, R.M. Mendes, and M. Castanheira Resistance Surveillance Programme report for European nations (2011) 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27-30 April 2013, Berlin, Germany 2013 European Society of Clinical Microbiology and Infectious Diseases Basel, Switzerland [poster 1503]
21. S.K. Bouchillon, R.E. Badal, D.J. Hoban, and S.P. Hawser Antimicrobial susceptibility of inpatient urinary tract isolates of Gram-negative bacilli in the United States: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009-2011 Clin Ther 35 2013 872 877
22. D.J. Hoban, S.K. Bouchillon, S.P. Hawser, R.E. Badal, V.J. Labombardi, and J. DiPersio Susceptibility of Gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) Antimicrob Agents Chemother 54 2010 3031 3034
23. J. Van Eldere Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections J Antimicrob Chemother 51 2003 347 352 (Pubitemid 36231155)
24. J.M. Blondeau A review of the comparative in vitro activities of 12 antimicrobial agents with a focus on 5 new 'respiratory quinolones' J Antimicrob Chemother 43 Suppl. B 1999 1 11 (Pubitemid 29231787)
25. J.A. Hoogkamp-Korstanje In vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections J Antimicrob Chemother 40 1997 427 431 (Pubitemid 27437965)
26. M. Woodhead, F. Blasi, S. Ewig, J. Garau, G. Huchon, M. Ieven Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases Guidelines for the management of adult lower respiratory tract infections - full version Clin Microbiol Infect 17 Suppl. 6 2011 E1 E59
27. Y-J. Lee, H-Y. Liu, and Y-C. Lin Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use Int J Antimicrob Agents 35 2010 261 264
28. M. Andre, A. Vernby, I. Odenholt, C.S. Lundborg, I. Axelsson, and M. Eriksson et al. Diagnosis-prescribing surveys in 2000, 2002 and 2005 in Swedish general practice: consultations, diagnosis, diagnostics and treatment choices Scand J Infect Dis 40 2008 648 654
29. T.M. Hooton, P.L. Roberts, and A.E. Stapleton Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial JAMA 307 2012 583 589
30. European Association of Urology Guidelines 2012 http://www.uroweb.org/ fileadmin/guidelines/2012-Guidelines-large-text-print-total-file.pdf [accessed 22.08.13]
31. E. De Vecchi, S. Sitia, C.L. Romano, C. Ricci, R. Mattina, and L. Drago Aetiology and antibiotic resistance patterns of urinary tract infections in the elderly: a 6-month study J Med Microbiol 62 2013 859 863
32. G. Bonkat, G. Muller, O. Braissant, R. Frei, S. Tschudin-Suter, and M. Rieken et al. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-ß-lactamase-producing Escherichia coli urinary isolates World J Urol 31 2013 1427 1432
33. M.E. Falagas, and D.E. Karageorgopoulos Extended spectrum ß-lactamase-producing organisms J Hosp Infect 73 2009 345 354
34. P.L. Lu, Y.C. Liu, H.S. Toh, Y.L. Lee, Y.M. Liu, and C.M. Ho et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Int J Antimicrob Agents 40 Suppl. 2012 S37 S43
35. P.D. Croughs, B. Li, J.A. Hoogkamp-Korstanje, and E. Stobberingh Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in The Netherlands Eur J Clin Microbiol Infect Dis 32 2013 283 288
36. J.M. Blondeau, and D. Vaughan In vitro activity of 19 antimicrobial agents against 3513 nosocomial pathogens collected from 48 Canadian medical centres Int J Antimicrob Agents 15 2000 213 219 (Pubitemid 30645471)
37. J.M. Blondeau, G. Hansen, K.L. Metzler, S. Borsos, L.B. Irvine, and L. Blanco In vitro susceptibility of 4903 bacterial isolates to gemifloxacin - an advanced fluoroquinolone Int J Antimicrob Agents 22 2003 147 154 (Pubitemid 36970174)
38. C.E. Edmiston, C.J. Krepel, G.R. Seabrook, L.R. Somberg, A. Nakeeb, and R.A. Cambria et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections Antimicrob Agents Chemother 48 2004 1012 1016 (Pubitemid 38280357)
39. I.C. Gyssens, M. Dryden, P. Kujath, D. Nathwani, N. Schaper, and B. Hampel et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections J Antimicrob Chemother 66 2011 2632 2642
40. N.C. Schaper, M. Dryden, P. Kujath, D. Nathwani, P. Arvis, and P. Reimnitz et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study Infection 41 2013 175 186
41. E.J. Goldstein, J.S. Solomkin, D.M. Citron, and J.D. Alder Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin Clin Infect Dis 53 2011 1074 1080
42. E.J. Goldstein, D.M. Citron, Y.A. Warren, K.L. Tyrrell, C.V. Merriam, and H. Fernandez In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections Antimicrob Agents Chemother 50 2006 148 155 (Pubitemid 43042915)
43. W-C. Ko, and P-R. Hsueh Increasing extended-spectrum ß-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia-Pacific region: data from the SMART study 2002-2006 J Infect 59 2009 95 103
44. Y.J. Lau, Y.H. Chen, C.T. Huang, W.S. Lee, C.Y. Liu, and J.W. Liu et al. Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan J Microbiol Immunol Infect 45 2012 1 6
45. S.G. Amyes, F.M. Walsh, and J.S. Bradley Best in class: a good principle for antibiotic usage to limit resistance development? J Antimicrob Chemother 59 2007 825 826 (Pubitemid 47073350)
46. A. Dalhoff, and F.J. Schmitz In vitro antibacterial activity and pharmacodynamics of new quinolones Eur J Clin Microbiol Infect Dis 22 2003 203 221 (Pubitemid 36578906)
47. C.S. Lewin, P. Blakemore, Y.J. Drabu, and J.T. Smioth Loss of ciprofloxacin's second killing action in Escherichia coli that have developed 4-quinolone resistance during therapy J Antimicrob Chemother 26 1990 594 596 (Pubitemid 20346877)
48. E.G. Power, J.L. Munoz Bellido, and I. Phillips Detection of ciprofloxacin resistance in Gram-negative bacteria due to alterations in gyrA J Antimicrob Chemother 29 1992 9 17
49. H.B. Kim, C.H. Park, C.J. Kim, E.C. Kim, G.A. Jacoby, and D.C. Hooper Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period Antimicrob Agents Chemother 53 2009 639 645
50. C.A. DeRyke, X. Du, and D.P. Nicolau Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae J Antimicrob Chemother 58 2006 601 609 (Pubitemid 44288125)
51. M.W. Garrison, J.A. Schimmels, and M.J. Madaras-Kelly In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV Diagn Microbiol Infect Dis 47 2003 587 593 (Pubitemid 38058285)
52. N.R. Florea, P.R. Tessier, C. Zhang, C.H. Nightingale, and D.P. Nicolau Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae Antimicrob Agents Chemother 48 2004 1215 1221 (Pubitemid 38405475)
53. E. Pestova, J.J. Millichap, G.A. Noskin, and L.R. Peterson Intracellular targets of moxifloxacin: a comparison with other quinolones J Antimicrob Chemother 45 2000 583 590 (Pubitemid 30255636)
54. W.M. Scheld Maintaining fluoroquinolone class efficacy: review of influencing factors Emerg Infect Dis 9 2003 1 9 (Pubitemid 36110195)
55. P.E. Empey, H.R. Jennings, A.C. Thornton, R.P. Rapp, and M.E. Evans Levofloxacin failure in a patient with pneumococcal pneumonia Ann Pharmacother 35 2001 687 690 (Pubitemid 32523601)
56. R. Davidson, R. Cavalcanti, J.L. Brunton, D.J. Bast, J.C. de Azavedo, and P. Kibsey et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N Engl J Med 346 2002 747 750 (Pubitemid 34983995)
57. M.B. Kays, D.W. Smith, M.E. Wack, and G.A. Denys Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia Pharmacotherapy 22 2002 395 399 (Pubitemid 34205178)
58. M. De Cueto, J.M. Rodríguez, M.J. Soriano, L. López-Cerero, J. Venero, and A. Pascual Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a pre-existing parC mutation J Clin Microbiol 46 2008 1558 1560 (Pubitemid 351563619)
59. K.S. Kaye, Z.A. Kanafani, A.E. Dodds, J.J. Engemann, S.G. Weber, and Y. Carmeli Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa Antimicrob Agents Chemother 50 2006 2192 2196 (Pubitemid 43807542)
60. C. Fogarty, A. Torres, S. Choudhri, D. Haverstock, J. Herrington, and J. Ambler Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia Int J Clin Pract 59 2005 1253 1259 (Pubitemid 43904492)
61. S. Noviello, F. Ianniello, S. Leone, and S. Esposito Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens J Antimicrob Chemother 52 2003 869 872 (Pubitemid 37407820)
62. S. Malhotra-Kumar, L. Van Heirstraeten, C. Lammens, S. Chapelle, and H. Goossens Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin J Antimicrob Chemother 63 2009 886 894
63. D.E. Karageorgopoulos, S. Maraki, A.C. Vatopoulos, G. Samonis, G.C. Schito, and M.E. Falagas Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece Eur J Clin Microbiol Infect Dis 32 2013 1417 1422
64. O. Burkhardt, and T. Welte 10 years' experience with the pneumococcal quinolone, moxifloxacin Exp Rev Anti Infect Ther 7 2009 645 668
65. P.D. Lister Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication Antimicrob Agents Chemother 46 2002 69 74 (Pubitemid 34031604)
66. P.D. Lister, and C.C. Sanders Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae J Antimicrob Chemother 47 2001 811 818 (Pubitemid 32519829)
67. C.H. Nightingale Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics Pharmacotherapy 20 2000 245 256 (Pubitemid 30140743)
68. P.G. Ambrose, D.M. Grasela, T.H. Grasela, J. Passarell, H.B. Mayer, and P.F. Pierce Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections Antimicrob Agents Chemother 45 2001 2793 2797 (Pubitemid 32906673)
69. J.K. Thomas, A. Forrest, S.M. Bhavnani, J.M. Hyatt, A. Cheng, and C.H. Ballow et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy Antimicrob Agents Chemother 42 1998 521 527 (Pubitemid 28114802)
70. K.L. LaPlante, M.J. Rybak, B. Tsuji, T.P. Lodise, and G.W. Kaatz Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin Antimicrob Agents Chemother 51 2007 1315 1320 (Pubitemid 46586811)
71. P. Kontou, K. Chatzika, G. Pitsiou, I. Stanopoulos, P. Argyropoulou-Pataka, and I. Kioumis Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease Antimicrob Agents Chemother 55 2011 4149 4153
72. K. Drlica, and F-J. Schmitz Therapeutic options in an era of decreasing antimicrobial susceptibility J Chemother 14 2002 5 12 (Pubitemid 34297844)
73. C. Urban, N. Rahman, X. Zhao, N. Mariano, S. Segal-Maurer, and K. Drlica et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy J Infect Dis 184 2001 794 798 (Pubitemid 32826434)
74. K. Matsuo, M. Azuma, M. Kasai, I. Hanji, I. Kimura, and T. Kosugi et al. Investigation of the clinical efficacy and dosage of intravenous ciprofloxacin in patients with respiratory infection J Pharm Pharm Sci 11 2009 111s 117s
75. J.M. Blondeau, X. Zhao, G. Hansen, and K. Drlica Mutant prevention concentrations of fluoroquinolones for isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 433 438 (Pubitemid 32105277)
76. A. Soman, D. Honeybourne, J. Andrews, G. Jevons, and R. Wise Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy J Antimicrob Chemother 44 1999 835 838
77. B. Capitano, H.M. Mattoes, E. Shore, A. O'Brien, S. Braman, and C. Sutherland et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin and azithromycin in older adults Chest 125 2004 965 973 (Pubitemid 38367287)
78. L.A. Mandell, R.G. Wunderink, A. Anzueto, J.G. Bartlett, G.D. Campbell, N.C. Dean Infectious Diseases Society of America; American Thoracic Society Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 Suppl. 2 2007 S27 S72 (Pubitemid 46290553)
79. I. Odenholt, and O. Cars Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model J Antimicrob Chemother 58 2006 960 965
80. T.E. Albertson, N.C. Dean, A.A. El Solh, M.H. Gotfried, C. Kaplan, and M.S. Niederman Fluoroquinolones in the management of community-acquired pneumonia Int J Clin Pract 64 2010 378 388
81. D. Jonas, I. Engels, C. Friedhoff, B. Spitzmüller, F.D. Daschner, and U. Frank Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila J Antimicrob Chemother 47 2001 147 152 (Pubitemid 32149518)
82. D. Breilh, J. Jougon, S. Djabarouti, J.B. Gordien, F. Xuereb, and J.F. Velly et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state J Chemother 15 2003 558 562 (Pubitemid 38241404)
83. M. Müller, H. Stass, M. Brunner, J.G. Möller, E. Lackner, and H.G. Eichler Penetration of moxifloxacin into peripheral compartments in humans Antimicrob Agents Chemother 43 1999 2345 2349 (Pubitemid 29471207)
84. O. Burkhardt, H. Derendorf, D. Jäger, V. Kumar, R. Madabushi, and K. Röhl et al. Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis Scand J Infect Dis 38 2006 904 908 (Pubitemid 44499425)
85. L. Malincarne, M. Ghebregzabher, M.V. Moretti, A.M. Egidi, B. Canovari, and G. Tavolieri et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty J Antimicrob Chemother 57 2006 950 954
86. J. Majcher-Peszynska, M. Sass, S. Schipper, V. Czaika, A. Gussmann, and R. Lobmann et al. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort Eur J Clin Pharmacol 67 2011 135 142
87. M. Wirtz, J. Kleeff, S. Swoboda, I. Halaceli, H.K. Geiss, and T. Hoppe-Tichy et al. Moxifloxacin penetration into human gastrointestinal tissues J Antimicrob Chemother 53 2004 875 877 (Pubitemid 38660296)
88. H. Stass, A.D. Rink, H. Delesen, D. Kubitza, and K.H. Vestweber Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis J Antimicrob Chemother 58 2006 693 696 (Pubitemid 44288143)
89. A.D. Rink, H. Stass, H. Delesen, D. Kubitza, and K.H. Vestweber Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess Clin Drug Invest 28 2008 71 79
90. D. Fabre, F. Bressolle, R. Gomeni, C. Arich, F. Lemesle, and H. Beziau et al. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa Antimicrob Agents Chemother 35 1991 2521 2525
91. T. Bergan Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses Am J Med 82 1987 97 102
92. A.W. Chow, M.S. Benninger, I. Brook, J.L. Brozek, E.J. Goldstein, and L.A. Hicks et al. Clinical practice guideline for acute bacterial rhinosinusitis in children and adults Clin Infect Dis 54 2012 e72 e112
93. W.J. Fokkens, V.J. Lund, J. Mullol, C. Bachert, I. Alobid, and F. Baroody et al. European position paper on rhinosinusitis and nasal polyps 2012 Rhinol Suppl 23 2012 1 298
94. G.M. Trenholme, B.A. Schmitt, J. Spear, L.C. Gvazdinskas, and S. Levin Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections Am J Med 87 1989 116S 118S (Pubitemid 20005160)
95. A. Anzueto, M.S. Niederman, J. Pearle, M.I. Restrepo, A. Heyder, and S.H. Choudhri Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy Clin Infect Dis 42 2006 73 81 (Pubitemid 41832083)
96. A. Torres, J. Garau, P. Arvis, J. Carlet, S. Choudhri, and A. Kureishi et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial Clin Infect Dis 46 2008 1499 1509 (Pubitemid 351706729)
97. C. Wenisch, R. Krause, M. Szell, and H. Laferl Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment Infection 34 2006 190 195 (Pubitemid 44214502)
98. R.P. Rapp, M. Billeter, J. Hatton, A.B. Young, P.A. Tibbs, and R.J. Dempsey Intravenous ciprofloxacin versus ceftazidime for the treatment of nosocomial pneumonia and urinary tract infection Clin Pharm 10 1991 49 55
99. R. Saginur, G. Garber, G. Darling, S. Shafran, W. Cameron, and G. Jones et al. Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia Can J Infect Dis 8 1997 89 94 (Pubitemid 27223538)
100. S. Kljucar, K.L. Rost, and H. Landen Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients Pneumologie 56 2002 599 604 [in German] (Pubitemid 35335081)
101. M.P. Fink, D.R. Snydman, M.S. Niederman, K.V. Leeper Jr., R.H. Johnson, and S.O. Heard et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin Antimicrob Agents Chemother 38 1994 547 557 (Pubitemid 24072247)
102. M. Miravitlles Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD Int J Chron Obstruct Pulmon Dis 2 2007 191 204 (Pubitemid 350110894)
103. R. Wilson, and A. Macklin-Doherty The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis Expert Rev Respir Med 6 2012 481 492
104. D. Hautamaki, T. Bruya, and A. Kureishi Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis Today's Ther Trends 19 2001 117 136 (Pubitemid 32487883)
105. J. Urueta-Robledo, H. Ariza, J.R. Jardim, A. Caballero, A. García-Calderón, and C.F. Amábile-Cuevas et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: The Latin American Cohort Respir Med 100 2006 1504 1511 (Pubitemid 44089371)
106. R. Wilson, L. Allegra, G. Huchon, J.L. Izquierdo, P. Jones, T. Schaberg MOSAIC Study Group Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis Chest 125 2004 953 964 (Pubitemid 38367286)
107. H. Lode, J. Eller, A. Linnhoff, M. Ioanas Evaluation of Therapy-Free Interval in COPD Patients Study Group Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval Eur Respir J 24 2004 947 953 (Pubitemid 39642284)
108. R. Wilson, P. Jones, T. Schaberg, P. Arvis, I. Duprat-Lomon, P.P. Sagnier MOSAIC Study Group Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis Thorax 61 2006 337 342
109. R. Wilson, A. Anzueto, M. Miravitlles, P. Arvis, J. Alder, and D. Haverstock et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results Eur Respir J 40 2012 17 27 Erratum in: Eur Respir J 2012;40:800
110. M.S. Niederman, A. Anzueto, S. Sethi, S. Choudhri, A. Kureishi, and D. Haverstock et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents Respir Med 100 2006 1781 1790 (Pubitemid 44283756)
111. S. Antonela Antoniu Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa Expert Rev Anti Infect Ther 10 2012 1439 1446
112. D. Azoicai, and S.A. Antoniu MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections Expert Opin Investig Drugs 22 2013 267 276
113. S. Sethi, S.I. Rennard, M. Miravitlles, F.J. Martinez, J.F. Donohue, and A. Anzueto et al. A phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (MP-376) administered for 5 days every 28 days to prevent acute exacerbations in high risk COPD patients Am J Respir Crit Care Med 185 2012 A3037
114. S.H. Lee, J. Teo, D. Heng, W.K. Ng, H.K. Chan, and R.B. Tan Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation Eur J Pharm Biopharm 2012 pii:S0939-6411(12)00285-8
115. R. Siegert, P. Gehanno, P. Nikolaisis, D. Bagger-Sjöbäck, J.M. Ibanez, and B. Hampel et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group Respir Med 94 2000 337 344 (Pubitemid 30323568)
116. S. Rakkar, K. Roberts, B.F. Towe, S.M. Flores, A. Heyd, and J. Warner Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience Int J Clin Pract 55 2001 309 315 (Pubitemid 32605792)
117. J.R. Arrieta, A.S. Galgano, E. Sakano, X. Fonseca, C.F. Amábile-Cuevas, and G. Hernández-Oliva et al. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis Am J Otolaryngol 28 2007 78 82 (Pubitemid 46386313)
118. J.M. Klossek, R. Siegert, P. Nikolaidis, P. Arvis, M.A. Leberre Sinusitis Study Group Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults J Laryngol Otol 117 2003 43 51 (Pubitemid 36084237)
119. K.N. Keating, H.S. Friedman, and E.M. Perfetto Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges Curr Med Res Opin 22 2006 327 333 (Pubitemid 44296756)
120. H. Ariza, R. Rojas, P. Johnson, R. Gower, A. Benson, and J. Herrington et al. Eradication of common pathogens at Days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis BMC Ear Nose Throat Disord 6 2006 8
121. P. Giordano, J. Song, P. Pertel, J. Herrington, and S. Kowalsky Sequential intravenous/oral moxifloxacin versus intravenous piperacillin- tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection Int J Antimicrob Agents 26 2005 357 365 (Pubitemid 41483465)
122. D.R. Guay Moxifloxacin in the treatment of skin and skin structure infections Ther Clin Risk Manag 2 2006 417 434 (Pubitemid 44895992)
123. P. Kujath, and C. Kujath Complicated skin, skin structure and soft tissue infections - are we threatened by multi-resistant pathogens? Eur J Med Res 15 2010 544 553
124. R. Vick-Fragoso, G. Hernández-Oliva, J. Cruz-Alcázar, C.F. Amábile-Cuevas, P. Arvis, and P. Reimnitz et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections Infection 37 2009 407 417
125. D.R. Graham, D.A. Talan, R.L. Nichols, C. Lucasti, M. Corrado, and N. Morgan et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate
126. R. Bellmann, G. Kuchling, P. Dehghanyar, M. Zeitlinger, E. Minar, and B.X. Mayer et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections Br J Clin Pharmacol 57 2004 563 568 (Pubitemid 38582175)
127. A. Landsman, P.A. Blume, D.A. Jordan Jr., D. Vayser, and A. Gutierrez An open-label, three-arm pilot study of the safety and efficacy of topical Microcyn Rx wound care versus oral levofloxacin versus combined therapy for mild diabetic foot infection J Am Podiatr Med Assoc 101 2011 484 496
128. C. Davis Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group Clin Ther 16 1994 505 521 (Pubitemid 24321683)
129. B.A. Lipsky, B. Miller, B. Schwartz, D.C. Henry, T. Nolan, and A. McCabe et al. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections Clin Ther 21 1999 675 690 (Pubitemid 29252090)
130. G.A. Pankey Multicenter, phase IV evaluation of intravenous ciprofloxacin as initial therapy in patients with lower respiratory tract, urinary tract, and skin/skin structure infections Clin Ther 17 1995 353 365
131. M. Müller, M. Brunner, U. Hollenstein, C. Joukhadar, R. Schmid, and E. Minar et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients Antimicrob Agents Chemother 43 1999 2056 2058 (Pubitemid 29395209)
132. C. Joukhadar, N. Klein, M. Frossard, E. Minar, H. Stass, and E. Lackner et al. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease Clin Pharmacol Ther 70 2001 532 539 (Pubitemid 34008410)
133. J.S. Solomkin, J.E. Mazuski, J.S. Bradley, K.A. Rodvold, E.J. Goldstein, and E.J. Baron et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Clin Infect Dis 50 2010 133 164 Erratum in: Clin Infect Dis 2010;50:1695
134. J.S. Solomkin, J.E. Mazuski, J.S. Bradley, K.A. Rodvold, E.J. Goldstein, and E.J. Baron et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Surg Infect (Larchmt) 11 2010 79 109
135. J. Solomkin, Y.-P. Zhao, E.-L. Ma, M.J. Chen, B. Hampel DRAGON Study Team Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections Int J Antimicrob Agents 34 2009 439 445
136. M.A. Malangoni, J. Song, J. Herrington, S. Choudhri, and P. Pertel Randomized controlled trial of moxifloxacin compared with piperacillin- tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections Ann Surg 244 2006 204 211 (Pubitemid 44305534)
137. G. Weiss, P. Reimnitz, B. Hampel, E. Muehlhofer, H. Lippert AIDA Study Group Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (AIDA) J Chemother 21 2009 170 180
138. J.J. De Waele, J.M. Tellado, J. Alder, P. Reimnitz, M. Jensen, and B. Hampel et al. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study Int J Antimicrob Agents 41 2013 57 64
139. A.K. Madan Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections Clin Ther 26 2004 1564 1577 (Pubitemid 39643017)
140. D. Hatzaki, G. Poulakou, I. Katsarolis, N. Lambri, M. Souli, and I. Deliolanis et al. Cefditoren: comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients BMC Infect Dis 12 2012 228
141. A. Ronald The etiology of urinary tract infection: traditional and emerging pathogens Am J Med 113 Suppl. 1A 2002 14S 19S (Pubitemid 34756641)
142. M. Tinelli, M.A. Cataldo, E. Mantengoli, C. Cadeddu, E. Cunietti, and F. Luzzaro et al. Epidemiology and genetic characteristics of extended-spectrum ß-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities J Antimicrob Chemother 67 2012 2982 2987
143. S. Auer, A. Wojna, and M. Hell Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-ß- lactamase-producing Escherichia coli Antimicrob Agents Chemother 54 2010 4006 4008
144. Y.H. Chen, W.C. Ko, and P.R. Hsueh The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens Eur J Clin Microbiol Infect Dis 31 2012 1699 1704
145. J. Peterson, S. Kaul, and M. Khashab A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis Urology 71 2008 17 22 (Pubitemid 351173271)
146. D.A. Talan, K.G. Naber, J. Palou, and D. Elkharrat Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infection Int J Antimicrob Agents 23 Suppl. 1 2004 S54 S66 (Pubitemid 38376050)
147. G.M. Arcieri, N. Becker, B. Esposito, E. Griffith, A. Heyd, and C. Neumann et al. Safety of intravenous ciprofloxacin Am J Med 87 1989 92S 97S
148. J.S. Wolfson, and D.C. Hooper Fluoroquinolone antimicrobial agents Clin Microbiol Rev 2 1989 378 424 (Pubitemid 19249268)
149. P.M. Tulkens, P. Arvis, and F. Kruesmann Moxifloxacin safety: an analysis of 14 years of clinical data Drugs R D 12 2012 71 100
150. F. Van Bambeke, and P.M. Tulkens Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes Drug Saf 32 2009 369 378
151. P. Ball, R. Stahlmann, and R. Kubin Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies Clin Ther 26 2004 940 950 (Pubitemid 39141801)
152. R. Stahlmann, and H.M. Lode Risks associated with the therapeutic use of fluoroquinolones Expert Opin Drug Saf 12 2013 497 505
153. V.T. Andriole, D.C. Haverstock, and S.H. Chodhri Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials Drug Saf 28 2005 443 452 (Pubitemid 40733730)
154. J. Morganroth, J.P. DiMarco, A. Anzueto, M.S. Niederman, S. Choudhri CAPRIE Study Group A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients with community-acquired pneumonia Chest 128 2005 3398 3406 (Pubitemid 41698670)
155. K.F. Croom, and K.L. Goa Levofloxacin: a review of its use in the treatment of bacterial infections in the United States Drugs 63 2003 2769 2802 (Pubitemid 38049994)
156. I.A. Dhalla, M.M. Mamdani, A.E. Simor, A. Kopp, P.A. Rochon, and D.N. Juurlink Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother 50 2006 3216 3219 (Pubitemid 44396444)
157. S. Fuchs, Z. Simon, and M. Brezis Fatal hepatic failure associated with ciprofloxacin Lancet 343 1994 738 739 (Pubitemid 24087878)
158. B.K. Grassmick, V.T. Lehr, and A.S. Sundareson Fulminant hepatic failure possibly related to ciprofloxacin Ann Pharmacother 26 1992 636 639
159. H. Lode, and M. Schmidt-Ioanas Moxifloxacin: update and perspectives after 8 years of usage Exp Rev Respir Med 2 2008 443 453
160. L.Y. Park-Wyllie, D.N. Juurlink, and A. Kopp Outpatient gatifloxacin therapy and dysglycemia in older adults N Engl J Med 354 2006 1 10
161. G.S. Tillotson, and P. Ball Fluoroquinolone safety profiles - a review Today's Ther Trends 1 2003 419 435
162. R.C. Owens, and P.G. Ambrose Antimicrobial safety: focus on fluoroquinolones Clin Infect Dis 40 2005 S456 S469
163. M.E. Falagas, P.I. Rafailidis, and E.S. Rosmarakis Arrhythmias associated with fluoroquinolone therapy Int J Antimicrob Agents 29 2007 374 379 (Pubitemid 46349590)
164. R. Frothingham Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin Pharmacotherapy 21 2001 1468 1472 (Pubitemid 33117251)
165. F. Lapi, M. Wilchesky, A. Kezouh, J.I. Benisty, P. Ernst, and S. Suissa Fluoroquinolones and the risk of serious arrhythmias: a population-based study Clin Infect Dis 55 2012 1457 1465
166. US Food and Drug Administration International Conference on Harmonization (ICH) - guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Current Step 4 version dated 12 May 2005. http://www.fda.gov/RegulatoryInformation/ Guidances/ucm129335.htm [accessed 22.08.13].
167. E. Poluzzi, E. Raschi, D. Motola, U. Moretti, and F. De Ponti Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System Drug Saf 33 2010 303 314
168. W. Haverkamp, F. Kruesmann, A. Fritsch, D. van Veenhuyzen, and P. Arvis Update on the cardiac safety of moxifloxacin Curr Drug Saf 7 2012 149 163
169. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management and prevention of COPD 2013 GOLD http://www.goldcopd.org [accessed 22.08.13]
170. J. Vestbo, S.S. Hurd, A.G. Agustí, P.W. Jones, C. Vogelmeier, and A. Anzueto et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 187 2013 347 365
171. D.L. Stevens, A.L. Bisno, H.F. Chambers, E.D. Everett, P. Dellinger, and E.J. Goldstein et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections Clin Infect Dis 41 2005 1373 1406 (Pubitemid 41581713)
172. American Thoracic Society, and Infectious Diseases Society for America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416